Business
Novo Nordisk shares plunge after CagriSema obesity drug trial disappoints - Reuters
Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.
By: Reuters
- Dec 21 2024
- 0
- 0 Views
